Johnson & Johnson 2025 Q2 Earnings ReportFinancial statementsJohnson & Johnson's Q2 2025 earnings report highlights strong growth across Innovative Medicine and MedTech, driven by oncology breakthroughs and cardiovascular innovation despite industry headwinds.
Johnson & Johnson 2025 H1 PerformanceFinancial statementsJohnson & Johnson reports $45.64B revenue in H1 2025, driven by oncology growth. Darzalex hits $6.8B, Carvykti surges toward $2B. Neuroscience and immunology portfolios evolve amid strategic acquisitions.
Johnson & Johnson's Q1 2025 Financial reportJohnson & JohnsonJohnson & Johnson's Q1 2025 report shows a 135% sales surge for CARVYKTI, a CAR-T therapy co-developed with Legend Biotech, with projected annual sales hitting $2B. Oncology drug sales also saw strong growth.
Top 10 Pharmaceutical Giants' R&D Investments in 2024Market TrendIn 2024, pharmaceutical giants face a quiet battle over innovation and efficiency. From Merck’s 41% R&D drop to AbbVie’s bold growth, their strategies and investments reveal shifting power in the industry. A glimpse into the future of drug development.
2024 Global CAR-T Sales PerformanceCAR-TDiscover the sales performance of CAR-T therapies in 2024, including Kymriah, Yescarta, Breyanzi, and more. Explore trends, growth, and challenges in the CAR-T cell therapy market across the US and beyond.
Top 10 Global Pharmaceutical Giants in Oncology Business for 2024OncologyDiscover the top 10 pharmaceutical giants leading the oncology industry in 2024. From Merck's dominance with Keytruda to AstraZeneca's rise, these companies are making strides in cancer treatment, innovation, and growth.
2024 FDA Issued CRLsFDAThe FDA issued Complete Response Letters (CRLs) for multiple drug applications in 2024, citing concerns about efficacy, safety, and manufacturing. Learn about the rejected drugs, reasons behind CRLs, and their impact on pharmaceutical companies.
Johnson & Johnson 2024 Q4 Financial ReportFinancial statementsJohnson & Johnson's 2024 financial report reveals a 4.3% revenue increase, with Daratumumab (Darzalex) reaching $11.67B and Carvykti seeing a 92.7% growth. Key oncology, immunology, and neuroscience advancements also highlighted.
Top 10 Immunology Drugs to Watch in 2024AbbVieExplore the top 10 best-selling immunology drugs of 2023, including Humira, Dupixent, Stelara, and more. Discover how these innovative therapies are shaping the market, driving clinical breakthroughs, and overcoming competitive challenges.
EN
Agricultural News
Food News
Industrial News
Cosmetic News
Pharmaceutical News
Science News
